Cardarine (GW501516) – Mechanism of Action and What Research Shows
GW501516 is one of the few compounds for which the most important fact is not what it does, but why its development was stopped.
GW501516 is one of the few compounds for which the most important fact is not what it does, but why its development was stopped. The molecule was created in the 1990s as a metabolic drug candidate and entered early human studies. Its clinical development was later discontinued after findings from long-term toxicology studies in animals. This article explains the PPARδ mechanism, the research evidence and the reasons the programme was halted. It does not include use protocols, because publishing them for a compound with this profile would be irresponsible.
All substances discussed in this article are research compounds and are not intended for human consumption. Descriptions of their activity are based solely on laboratory findings and experimental observations, not on clinical testing.
What is GW501516?
GW501516, also known as Cardarine or Endurobol, is a synthetic, selective PPARδ receptor agonist. PPARδ is the delta isoform of the peroxisome proliferator-activated nuclear receptor family. The compound was developed through a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals as a drug candidate for metabolic disorders and dyslipidaemia (Pelton, 2006, PMID 16625823).
Two points need to be made immediately because they are often confused in everyday discussion. First, GW501516 is not a SARM. It does not act on the androgen receptor, but on a completely different nuclear receptor in the PPAR family. Second, it is not a dietary supplement. It is a research-grade compound that has not been approved for marketing in any jurisdiction.
Mechanism of action: the PPARδ pathway
PPARδ is a transcription factor found in skeletal muscle, adipose tissue and the liver, among other tissues. After binding an agonist, it forms a heterodimer with the RXR receptor and binds to regulatory sequences in DNA, changing the expression of genes involved in cellular energy metabolism.
Fatty acid oxidation
The main transcriptional shift described after PPARδ activation involves moving muscle-cell metabolism towards fatty acid oxidation as a preferred energy substrate. Experimental models show increased expression of genes involved in lipid transport and beta-oxidation.
Where does the term “exercise mimetic” come from?
GW501516 became popular in sporting circles largely because of one widely discussed publication. A 2008 paper in Cell reported that PPARδ agonists, combined with training, changed muscle-fibre profiles and endurance parameters in mice. The authors used the term “exercise mimetics” (Narkar et al., 2008, PMID 18674809).
This study was conducted in mice. It describes a mechanism in an animal model and is not evidence of efficacy or safety in humans. Later literature also discusses the pharmacological modulation of exercise adaptations together with its limitations and risks (Weihrauch and Handschin, 2018, PMID 29061342).
What was actually studied in humans?
Contrary to a common claim, GW501516 did enter early studies involving human participants. These were short-term metabolic and lipid studies, however, not studies of weight loss or athletic performance.
- A study in men with moderate obesity assessed how PPARδ activation affected metabolic parameters, oxidative stress and fatty acid oxidation (Risérus et al., 2008, PMID 18024853).
- Researchers also assessed effects on the lipid profile in participants with low HDL cholesterol and features of metabolic syndrome (Olson et al., 2012, PMID 22814748), as well as effects on lipoprotein metabolism in people with dyslipidaemia and central obesity (Ooi et al., 2011, PMID 21816786).
These studies involved small groups and short observation periods. None answered the question of long-term safety, which ultimately determined the fate of the entire programme.
Why was clinical development stopped?
This is the most important section of the article and the reason no use regimens are provided here.
Oncology signal in an animal model
A study published in Cancer Research in 2005 compared PPARγ and PPARδ agonists in a mouse model of mammary carcinogenesis induced by a progestin and a carcinogen. The outcome for PPARδ was clearly unfavourable: animals receiving GW501516 developed tumours more rapidly, and the tumours were adenosquamous and squamous-cell carcinomas. The authors linked this finding to increased PPARδ expression and activation of PDK1, a kinase with known oncogenic activity in mammary epithelium (Yin et al., 2005, PMID 15867396).
These are animal-model data and should be read as such. They cannot be transferred directly to humans. This does not make them irrelevant; it means that extrapolation in either direction would be methodologically unjustified. What happened after these findings is nevertheless important.
The consequence: the programme was halted
The manufacturer ended clinical development of GW501516 after long-term animal toxicology studies revealed tumours in multiple organs. The compound has never received marketing authorisation in any country and has no status as a medicinal product. This decision carries more informational weight than any single study: the organisation with access to the full preclinical data package chose to withdraw the molecule from development.
More recent observations from cellular models
The oncology issue did not end in 2005. A 2020 study examined invasive bladder-cancer cells exposed to GW501516 (Elie-Caille et al., 2020, PMID 32519230). A 2025 paper described how the compound may facilitate tumour immune escape by inhibiting phagocytosis (Qian et al., 2025, PMID 39993702). Both are studies in cellular models, not clinical trials.
No long-term human safety data
Because the clinical programme was stopped, there are no long-term human safety data for GW501516. Such data do not exist and are unlikely to be generated unless a party undertakes studies whose justification is questionable after the toxicology findings. Any exposure to the compound therefore takes place outside a documented safety framework.
Regulatory status and anti-doping note
WADA status: category S4.4.1, metabolic modulators. GW1516 (GW501516) appears in section S4.4 of the World Anti-Doping Agency Prohibited List, which includes PPARδ agonists and AMPK activators. It is prohibited at all times, both in and out of competition.
The compound has an exceptional status even among other prohibited substances. In March 2013, WADA issued a public health warning to athletes, a rare step that went beyond simply listing the substance. The warning was prompted by reports of black-market distribution and by the manufacturer’s information about toxicity identified in preclinical studies.
Detectability is not an open question. Methods have been developed for identifying GW501516 in anti-doping control (Pokrywka et al., 2014, PMID 25179079), including analysis of hair by LC/MS-MS with LC/HRMS confirmation (Kintz et al., 2020, PMID 32298044). The online trade in non-approved substances was discussed in the anti-doping context as early as 2011 (Thevis et al., 2011, PMID 21538997).
Harm reduction: practical implications
For a person subject to anti-doping control, exposure to GW501516 creates a real risk of disqualification. Detection methods include hair analysis, which can extend the detection window beyond urine alone. Because the compound is not a registered medicine, there is no route to obtain a Therapeutic Use Exemption. Independent of anti-doping control, the central issue remains that development of this molecule was stopped because of toxicology findings and no long-term human safety profile has been established. Its current status should always be checked against the latest version of the Prohibited List.
Frequently asked questions
Is Cardarine a SARM?
No. SARMs act on the androgen receptor, whereas GW501516 is an agonist of the PPARδ nuclear receptor. These are separate compound classes with different mechanisms and different classifications on the WADA Prohibited List.
Why did GW501516 never reach pharmacies?
Clinical development was stopped after long-term animal toxicology studies revealed tumours in multiple organs. The compound has not received marketing authorisation in any country.
Did the oncology studies involve humans?
No. The 2005 publication describes accelerated tumour formation in a mouse model of mammary carcinogenesis (PMID 15867396), while the more recent papers use cellular models. No human oncology trials were conducted. The absence of such data, combined with the preclinical signal, was central to stopping the programme.
What is the status of GW501516 in sport?
It is prohibited at all times under category S4.4, metabolic modulators. WADA also issued a public health warning about the compound in 2013. Validated detection methods exist, including analysis of hair samples.
Summary
GW501516 is a selective PPARδ agonist developed as a metabolic drug candidate and evaluated in early, short-term lipid studies involving human participants. Its mechanism, which shifts muscle metabolism towards fatty acid oxidation, is well described. The term “exercise mimetic” comes from a mouse study published in 2008. The toxicology findings are decisive when assessing the compound: accelerated tumour formation was observed in a mouse model of mammary carcinogenesis, and long-term animal studies revealed tumours in multiple organs, leading to the discontinuation of clinical development. GW501516 has no marketing authorisation in any jurisdiction, no long-term human safety data exist, and WADA lists it under category S4.4 as prohibited at all times. It was also the subject of a rare public health warning in 2013.
Product documentation
Research-material pages containing GW501516 and batch-specific analytical documentation: GW-501516 solution and GW-501516 capsules. These materials are intended solely for research applications.
Research materials with a related molecular target include GW-0742, another PPARδ agonist described in the literature. A different pathway, Rev-Erb rather than PPARδ, is represented by the Rev-Erb agonist compounds SR-9009 and SR-9011. Every item listed here has research-only status, and none is approved as a medicinal product.
References
- Yin Y, Russell RG, Dettin LE, et al. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 2005;65(9):3950-3957. PMID: 15867396
- Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809
- Pelton P. GW-501516 GlaxoSmithKline/Ligand. Curr Opin Investig Drugs. 2006;7(4):360-370. PMID: 16625823
- Risérus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57(2):332-339. PMID: 18024853
- Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012;32(9):2289-2294. PMID: 22814748
- Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011;96(10):E1568-E1576. PMID: 21816786
- Qian J, Guo Y, Khan B, Shi J, Hou Y. GW501516 facilitated tumor immune escape by inhibiting phagocytosis. Eur J Pharmacol. 2025;995:177418. PMID: 39993702
- Elie-Caille C, Lascombe I, Péchery A, Bittard H, Fauconnet S. Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure. Mol Cell Biochem. 2020;471(1-2):113-127. PMID: 32519230
- Kintz P, Ameline A, Gheddar L, Raul JS. Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS. Drug Test Anal. 2020;12(7):980-986. PMID: 32298044
- Pokrywka A, Cholbiński P, Kaliszewski P, et al. Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor delta (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). J Physiol Pharmacol. 2014;65(4):469-476. PMID: 25179079
- Thevis M, Geyer H, Thomas A, Schänzer W. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal. 2011;3(5):331-336. PMID: 21538997
- Weihrauch M, Handschin C. Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls. Biochem Pharmacol. 2018;147:211-220. PMID: 29061342